Day 2Peripheral vascular diseaseAorta

SOLACI CACI 2017 | Tipo II Endoleaks: Tratamiento obligatorio o un miedo infundado

solaci
solaci
468
0
Dr. Hugo Londero
Dr. Hugo Londero

Read articles on the main presentations of the second day of SOLACI-CACI 2017 Congress.

See the presentation by Dr. Hugo Londero, entitled “Tipo II Endoleaks: Tratamiento obligatorio o un miedo infundado”.

3Londero-HugoTypeII

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

Previous article
SOLACI CACI | TAVI: Evidencia para pacientes de riesgo intermedio
Next article
SOLACI CACI 2017 | CTO y CHIP Toolbox: Anatomía y Diseño de Guías Coronarias y MicroCatheters 101: Ingeniería para el Intervencionista”.
solaci
solaci

More articles by this author

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

Dr. Omar Tupayachi - 0
The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

Dr. Omar Tupayachi - 0
The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

FFR Assessment for the Selection of Hypertensive Patients Who Benefit from Renal Stenting

Dr. Omar Tupayachi - 0
Atherosclerotic renal artery stenosis (ARAS) represents one of the main causes of secondary hypertension (HTN) and is associated with a higher risk of renal...

Transcatheter Deep Vein Arterialization in Critical Limb Ischemia Without Revascularization Options

Dr. Juan Manuel Pérez - 0
Chronic limb-threatening ischemia in patients without conventional revascularization options represents one of the most challenging scenarios within peripheral arterial disease, with 1-year major amputation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Other

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right...
Dr. Omar Tupayachi -
SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Dr. Omar Tupayachi - 0
Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Dr. Omar Tupayachi - 0
Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

Dr. Omar Tupayachi - 0
The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...